Dendritic cell vaccination: New hope for the treatment of metastasized endocrine malignancies

Trends in Endocrinology and Metabolism

Volumn 14, Issue 4, 2003, Pages 156-162

  Schott, Matthias ^a   Seissler, Jochen ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CALCITONIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; MUCIN 1; PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P53; RAS PROTEIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL LYSATE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCRINE TUMOR; HUMAN; MEMORY CELL; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THYROID MEDULLARY CARCINOMA; VACCINATION;

EID: 0038746621     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(03)00033-X     Document Type: Review

References (69)

1. Coyle, A.J. and Gutierrez-Ramos, J.C. (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immun. 2, 203-209
2. + IFN-γ-producing T cells from tumor-infiltrating lymphocytes. J. Immunol. 164, 6633-6639
3. Berard, F. et al. (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535-1544
4. + T- helper and a T-killer cell. Nature 393, 474-478
5. Larsson, M. et al. (2001) Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur. J. Immunol. 31, 3432-3442
6. Heath, W.R. and Carbone, F.R. (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64
7. Grabbe, S. et al. (2000) Dendritic cells: multi-lineal and multi-functional. Immunol. Today 21, 431-433
8. Ardavin, C. et al. (2001) Origin and differentiation of dendritic cells. Trends Immunol. 22, 691-700
9. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252
10. Moser, M. and Murphy, K.M. (2000) Dendritic cell regulation of TH1-TH2 development. Nat. Immun. 1, 199-205
11. Tanaka, H. et al. (2000) Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J. Exp. Med. 192, 405-412
12. Jonuleit, H. et al. (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222
13. Jonuleit, H. et al. (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93, 243-251
14. Enk, A.H. et al. (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73, 309-316
15. Almand, B. et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766
16. Nouri-Shirazi, M. et al. (2000) Dendritic cell based tumor vaccines. Immunol. Lett. 74, 5-10
17. + T cells to secrete IL-4. Int. Immunol. 10, 1017-1026
18. Steinbrink, K. et al. (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93, 1634-1642
19. Koch, F. et al. (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184, 741-746
20. Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118
21. Romani, N. et al. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151
22. Reddy, A. et al. (1997) A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90, 3640-3646
23. Schattenberg, D. et al. (2000) Response of human monocyte-derived dendritic cells to immunostimulatory DNA. Eur. J. Immunol. 30, 2824-2831
24. Weiner, G.J. (2000) The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukocyte Biol. 68, 455-463
25. Boczkowski, D. et al. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472
26. Specht, J.M. et al. (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213-1221
27. Song, W. et al. (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256
28. Ashley, D.M. et al. (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177-1182
29. Wang, J. et al. (1998) Eliciting T cell immunity against poorlyimmunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516-5524
30. Tuting, T. et al. (1998) Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160, 1139-1147
31. Dhodapkar, M.V. et al. (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105, R9-R14
32. Roncarolo, M.G. et al. (2001) Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5-F9
33. + hematopoietic progenitor cells. Cancer Immunol. Immunother. 48, 118-122
34. Eggert, A.A. et al. (1999) Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59, 3340-3345
35. Murphy, G.P. et al. (2000) Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43, 59-62
36. Serody, J.S. et al. (2000) Tcell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164, 4961-4967
37. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384
38. Hsu, F.J. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58
39. Timmerman, J.M. et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526
40. Nestle, F.O. et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332
41. Thurner, B. et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678
42. Mackensen, A. et al. (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86, 385-392
43. Lau, R. et al. (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24, 66-78
44. Banchereau, J. et al. (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458
45. Tjoa, B.A. et al. (1998) Evaluation ofphase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39-44
46. Tjoa, B.A. et al. (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40, 125-129
47. Heiser, A. et al. (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417
48. + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352, 1358
49. Rieser, C. et al. (1999) Mature dendritic cells induce T-helper type-l-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int. 63, 151-159
50. Trefzer, U. et al. (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int. J. Cancer 85, 618-626
51. Heiser, A. et al. (2001) Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166, 2953-2960
52. Gong, J. et al. (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165, 1705-1711
53. Gong, J. et al. (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 97, 2715-2718
54. Schott, M. et al. (1999) Dendritic cell immunotherapy in disseminated parathyroid carcinoma. Lancet 353, 1188-1189
55. Schott, M. et al. (2001) Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin. Endocrinol. 55, 271-277
56. Bradwell, A.R. and Harvey, T.C. (1999) Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353, 370-373
57. Schott, M. et al. (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur. J. Endocrinol. 142, 300-306
58. Kebebew, E. et al. (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88, 1139-1148
59. Alters, S.E. et al. (1997) Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv. Exp. Med. Biol. 417, 519-524
60. Nair, S.K. et al. (1999) Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 82, 121-124
61. Morse, M.A. et al. (1999) A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5, 1331-1338
62. Schott, M. et al. (2001) Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 86, 4965-4969
63. Schott, M. et al. (2002) Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol. Immunother. 51, 663-668
64. Bachleitner-Hofmann, T. et al. (2002) Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J. Clin. Endocrinol. Metab. 87, 1098-1104
65. Stift, A. et al. (2003) Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol. 21, 135-142
66. Schuler-Thurner, B. et al. (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288
67. Rosenberg, S.A. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287
68. Marincola, F.M. et al. (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273
69. Rickinson, A.B. et al. (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405-431